High-dose intravenous gamma globulin reduces macrophage colony-stimulating factor levels in idiopathic thrombocytopenic purpura

International Journal of Hematology

Volumn 63, Issue 3, 1996, Pages 227-234

  Nomura, Shosaku ^a   Yasunaga, Kojiro ^b   Fujimura, Kingo ^c   Kuramoto, Atsushi ^c   Okuma, Minoru ^d   Nomura, Takeo ^e  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b KANSAI ELECTRIC POWER CO   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

High dose intravenous gamma globulin; Idiopathic thrombocytopenic purpura; Interleukin 6; Macrophage colony stimulating factor

Indexed keywords

COLONY STIMULATING FACTOR 1; IMMUNOGLOBULIN; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; THROMBOCYTOPENIC PURPURA;

EID: 0029929649     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/0925-5710(96)00447-1     Document Type: Article

References (38)

1. Karpatkin S. Autoimmune thrombocytopenic puapura. Blood 1980;56:329-343.
2. McMillan R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1981;304:1135-1147.
3. Ahn YS, Harrington WJ. Treatment of idiopathic throm-bocytopenic puapura. Ann Rev Med 1977;28:299-309.
4. Berchtold P, McMillan R. Therapy of chronic idiopathic thrombo-cytopenic purpura in adults. Blood 1989;74: 2309-2317.
5. Hilgartner MW, Larzkowsky PL, Smith CH. The use of azathioprine in refractory idiopathic thrombocytopenic purpura in children. Acta Paediatr Scand 1970;59: 409-413.
6. Ahn YS, Harrington WJ, Seelman RC, Eytel CS. Vincristine therapy of idiopathic and secondary throm-bocytopenias. N Engl J Med 1974;291:376-377.
7. Ahn YS. The treatment of idiopathic thrombocytopenic purpura with vinblastine-loaded platelets. N Engl J Med 1978;298:1101-1107.
8. Ahn YS, Harrington WJ, Simon SR, Mylvaganam R, Pall LM, So AG. Danazol for treatment of idiopathic thrombocytopenic purpura. N Engl J Med 1983;308: 1396-1399.
9. Imbach P, Barandun S, D'Appuzo V, et al. High dose intravenous gamma globulin for idiopathic throm-bocytopenic puapura in childhood. Lancet 1981;ii: 1228-1231.
10. Brox AG, Howson-Jan K, Fauser AA. Treatment of idiopathic thrombocytopenic purpura with ascorbate. Br J Haematol 1988;70:341-344.
11. Procter SJ, Jackson G, Garey P, et al. Improvement of platelet counts in steroid-unresponsive idiopathic immune thrombocytopenic purpura after short-course therapy with recombinant 2b interferon. Blood 1989; 74:1894-1897.
12. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gammaglobulin. N Engl J Med 1982;306:1254-1258.
13. Newland AC, Treleaven JG, Minchinton RM, Waters AH. High-dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet 1983;i:84-87.
14. McMillan R, Longmire RL, Tavassoli M, Armstrong S, Yelenosky R. In vitro platelet phagocytosis by splenic leukocytes in idiopathic thrombocytopenic purpura. N Engl J Med 1974;290:249-251.
15. Griffin FM Jr, Bianco L, Silverstein SC. Characterization of the macrophage receptor for complement and demonstration of its functional independence from the receptor for the Fc portion of immunoglobulin G. J Exp Med 1975;141:1269-1277.
16. Frank MM, Basta M, Fries LF. The effects of intravenous immunoglobulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol 1992;62(suppl.):82-86.
17. Budde U, Auch D, Schaefer G. Reticuloendothelial system Fc-receptor function in patients with immune throm-bocytopenia after treatment with high-dose intravenous immunoglobulin. Scand J Haematol 1986;37:125-129.
18. Bussel JB, Kimberly RP, Inman RD, et al. Intravenous gammaglobulin in the treatment of chronic idiopahtic thrombocytopenic purpura. Blood 1983;62:480-486.
19. Delfraissy JF, Tchernia G, Laurian Y, Wallon C. Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br J Haematol 1985;60:315-322.
20. Berchtold P, Dale GL, Tani P, McMillan R. Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood 1989;74:2414-2417.
21. 3 stimulated by anti-platelet antibodies. Clin Exp Immunol 1993;93:452-455.
22. Kawasaki ER, Ladner MB, Wang AM, et al. Molecular cloning of a complementary DNA encoding human macrophage specific colony-stimulating factor (CSF-1). Science 1985;230:291-296.
23. Motoyoshi K, Yoshida K, Hatake K, et al. Recombinant and native human urinary colony-stimulating factor peripheral blood monocytes. Exp Hematol 1989;17: 68-71.
24. Mufson RA, Aghajanian J, Wong GG, Woodhouse C, Morgan AC. Macrophage colony stimulating-factor enhances monocyte and macrophage antibody-dependent cell-mediated cytotoxity. Cell Immunol 1989;119: 182-192.
25. Wang M, Friedman H, Djeu JY. Enhancement of human monocyte function against candida albicans by the colony-stimulating factors (CSF): IL-3, granulocyte-macrophage CSF, and macrophage CSF. J Immunol 1989;143:671-677.
26. Suzu S, Yanai N, Sato-Somoto Y, et al. Characterization of macrophage colony-stimulating factor in body fluids by immunoblot analysis. Blood 1991;77:2160-2165.
27. Becker S, Warren MK, Haskill S. Colony-stimulating factor-induced monocyte survival and differentiation into macrophages in serum-free cultures. J Immunol 1987;139:3703-3709.
28. Warren MK, Ralph P. Macrophage growth factor CSF-1 stimulates human monocyte production of interferon, tumor necrosis factor, and colony stimulating activity. J Immunol 1986;137:2281-2285.
29. Yong K, Salooja N, Donahue RE, Hegde U, Linch DC. Human macrophage colony-stimulating factor levels are elevated in pregnancy and in immune thrombocytopenia. Blood 1992;80:2897-2902.
30. Zeigler ZR, Rosenfeld CS, Nemunaitis JJ, Besa EC, Shadduck RK. Increased macrophage colony-stimulating factor levels in immune thrombocytopenic purpura. Blood 1993;81:1251-1254.
31. Hanamura T, Motoyoshi K, Yoshida K, et al. Quantitation and identification of human monocytic colony-stimulating factor in human serum by enzyme-linked immunosorbent assay. Blood 1988;72:886-892.
32. Tsubakio T, Kurata Y, Yonezawa T, Kitani T. Quantification of platelet-associated IgG with a competitive solid-phase enzymeimmunoassay. Acta Haematol 1981; 66:251-256.
33. Magee DM, Wing EJ, Ampel NM, Waheed A, Shadduck RK. Macrophage colony-stimulating factor enhances the expression of Fc receptors on murine macrophages. Immunology 1987;62:373-378.
34. Cox LH, Downs T, Dagg K, Henthorn J, Burstein SA. Interleukin 6 mRNA and protein increase in vivo following induction of thrombocytopenia in mice. Blood 1991;77:286-293.
35. Janowska-Wieczorek A, Belch AR, Jacobs A, et al. Increased circulating colony-stimulating factor-1 in patients with preleukemia, leukemia and lymphoid malignancies. Blood 1991;77:1796-1720.
36. Tsubakio T, Kurata Y, Katagiri S et al. Alteration of T cell subsets and immunoglobulin synthesis in vitro during high-dose γ-globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immunol 1983;53: 697-702.
37. Dietrich G, Kaveri S-V, Kazatchkine MD. Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/ idiopathic network. Clin Immunol Immunopathol 1992; 62(suppl.):73-81.
38. Fries LF, Brickman CM, Frank MM. Monocyte receptors for the Fc portion of IgG increase in number in autoimmune hemolytic anemia and other hemolytic states and are decreased by glucocorticoid therapy. J Immunol 1983;131:1240-1245.